相关实验视频
Updated: Jul 4, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
114
基于细胞内信号和免疫代谢变化的风湿性关节炎的新型向疗法:叙述性审查
Marveh Rahmati1, Maria Paula Kwesiga2, Jiachen Lou3,4
1Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, 14166-14178 Tehran, Iran.
Frontiers in bioscience (Landmark edition)
|January 30, 2024
概括
类风湿性关节炎 (RA) 是一种影响关节的自身免疫性疾病. 了解其复杂的信号通路,包括代谢重编程,对于开发针对目前治疗方法耐药的患者的新疗法至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 分子生物学分子生物学
背景情况:
- 类风湿性关节炎 (RA) 是一种普遍存在的自身免疫性疾病,影响全球大约1%的人口.
- 具有对称性炎症性关节炎的特征,RA导致严重的骨和软骨损伤,这是由于免疫反应失调造成的.
- 基于生物制剂的疗法改善了生活质量,但治疗耐药性仍然是一个挑战.
研究的目的:
- 审查关键细胞内信号通路在风湿性关节炎 (RA) 进展中的作用.
- 为优化当前的RA疗法和开发新型分子抑制剂提供框架.
- 加强精准医学策略,用于难以治疗和多药耐药的RA病例.
主要方法:
- 本综述综合了当前关于RA病变发生过程中的细胞内信号通路的研究.
- 它检查了免疫细胞,细胞因子和代谢重编程的参与.
- 重点是与疾病进展和治疗向相关的途径.
主要成果:
- 涉及T细胞,B细胞和树突细胞的失调免疫反应是RA的核心.
- 特定的信号通路和代谢重编程对RA疾病的进展有显著的贡献.
- 针对这些途径为新的治疗策略提供了潜力.
结论:
- 更深入地了解RA中的细胞内信号通路对于推进精准医学至关重要.
- 识别这些途径的分子抑制剂可以克服对当前治疗的耐药性.
- 这些知识将有利于患有难以治疗和多药耐药性类风湿性关节炎的患者.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127

